| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
102,290,000 |
| Market
Cap: |
2.15(B) |
| Last
Volume: |
372,414 |
Avg
Vol: |
369,056 |
| 52
Week Range: |
$17.7 - $39.48 |
|
| Level
I Sector: |
Industrials |
| Level
II Sector: |
Diversified Services |
| Level
III Sector: |
Business Services |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ INDUSTRIAL |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of RNA chemistries and several modes of delivery, Co.'s therapies trigger the RNA interference (RNAi) mechanism to induce knockdown of target genes. Co. is focused on developing drugs for diseases with a genetic basis, typically characterized by the overproduction of one or more proteins that are involved with disease. Co.'s pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, and ARO-DUX4 for facioscapulohumeral muscular dystrophy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
3,000 |
3,000 |
| Total Buy Value |
$0 |
$0 |
$82,990 |
$82,990 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
3 |
3 |
| Total Shares Sold |
0 |
9,394 |
255,410 |
570,994 |
| Total Sell Value |
$0 |
$237,480 |
$8,556,496 |
$19,521,986 |
| Total People Sold |
0 |
1 |
10 |
11 |
| Total Sell Transactions |
0 |
1 |
20 |
36 |
| End Date |
2024-08-29 |
2024-05-28 |
2023-11-28 |
2022-11-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Oliver Tracie |
Chief Commercial Officer |
• – – |
2024-07-02 |
4 |
AS |
$25.28 |
$237,480 |
D/D |
(9,394) |
127,107 |
|
-13% |
|
| Vakiener Victoria |
Director |
– • – |
2024-05-02 |
4 |
AS |
$23.31 |
$41,935 |
D/D |
(1,799) |
30,205 |
|
-16% |
|
| Hamilton James C |
Chief Discovery/Trans Medicine |
• – – |
2024-04-01 |
4 |
S |
$28.03 |
$168,180 |
D/D |
(6,000) |
204,851 |
|
19% |
|
| Lu Hongbo |
Director |
– • – |
2024-03-20 |
4 |
B |
$27.50 |
$27,500 |
D/D |
1,000 |
33,680 |
2.39 |
1% |
|
| Lu Hongbo |
Director |
– • – |
2024-03-19 |
4 |
B |
$28.00 |
$28,000 |
D/D |
1,000 |
32,680 |
2.39 |
3% |
|
| Lu Hongbo |
Director |
– • – |
2024-03-18 |
4 |
B |
$27.49 |
$27,490 |
D/D |
1,000 |
31,680 |
2.39 |
2% |
|
| Lu Hongbo |
Director |
– • – |
2024-03-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
30,680 |
|
-0% |
|
| Myszkowski Kenneth Allen |
Chief Financial Officer |
• – – |
2024-03-06 |
4 |
S |
$35.19 |
$1,407,600 |
D/D |
(40,000) |
400,600 |
|
21% |
|
| Anzalone Christopher Richard |
Chief Executive Officer |
• • – |
2024-01-31 |
4 |
AS |
$32.16 |
$1,860,019 |
D/D |
(57,499) |
3,715,048 |
|
-23% |
|
| Anzalone Christopher Richard |
Chief Executive Officer |
• • – |
2024-01-31 |
4 |
OE |
$14.54 |
$836,035 |
D/D |
57,499 |
3,772,547 |
|
- |
|
| Hamilton James C |
Chief Discovery/Trans Medicine |
• – – |
2024-01-12 |
4 |
AS |
$36.47 |
$292,904 |
D/D |
(7,940) |
210,851 |
|
-32% |
|
| Ferrari Mauro |
Director |
– • – |
2024-01-11 |
4 |
AS |
$37.80 |
$119,787 |
D/D |
(3,147) |
60,778 |
|
-33% |
|
| Waddill William D. |
Director |
– • – |
2024-01-11 |
4 |
AS |
$37.81 |
$149,759 |
D/D |
(3,934) |
47,870 |
|
-33% |
|
| Vakiener Victoria |
Director |
– • – |
2024-01-11 |
4 |
AS |
$37.87 |
$179,813 |
D/D |
(4,720) |
32,001 |
|
-33% |
|
| Given Douglas B |
Director |
– • – |
2024-01-11 |
4 |
AS |
$37.76 |
$110,788 |
D/D |
(2,911) |
129,711 |
|
-33% |
|
| San Martin Javier |
Chief Medical Officer |
• – – |
2024-01-05 |
4 |
AS |
$34.11 |
$292,804 |
D/D |
(8,303) |
198,497 |
|
-30% |
|
| Oliver Tracie |
Chief Commercial Officer |
• – – |
2024-01-05 |
4 |
AS |
$33.89 |
$2,508 |
D/D |
(74) |
136,501 |
|
-30% |
|
| Myszkowski Kenneth Allen |
Chief Financial Officer |
• – – |
2024-01-05 |
4 |
AS |
$34.04 |
$567,910 |
D/D |
(16,104) |
440,600 |
|
-30% |
|
| Obrien Patrick |
COO and General Counsel |
• – – |
2024-01-05 |
4 |
AS |
$33.99 |
$805,716 |
D/D |
(22,841) |
464,385 |
|
-30% |
|
| Hamilton James C |
Chief Discovery/Trans Medicine |
– – – |
2024-01-05 |
4 |
AS |
$34.00 |
$1,130,748 |
D/D |
(32,143) |
218,791 |
|
-30% |
|
| San Martin Javier |
Chief Medical Officer |
• – – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
206,800 |
|
- |
|
| Oliver Tracie |
Chief Commercial Officer |
• – – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
136,575 |
|
- |
|
| Myszkowski Kenneth Allen |
Chief Financial Officer |
• – – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
456,704 |
|
- |
|
| Obrien Patrick |
COO and General Counsel |
• – – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
85,000 |
487,226 |
|
- |
|
| Obrien Patrick |
COO and General Counsel |
• – – |
2024-01-04 |
4 |
AS |
$32.63 |
$52,208 |
D/D |
(1,600) |
402,226 |
|
-27% |
|
350 Records found
|
|
Page 1 of 14 |
|
|
2.26 (12.03%) 
